FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Drug Deliv Transl Res / Intra-articular delivery of a nanocomplex comprising salmon ...
Drug delivery and translational research2018; 8(5); 1421-1435; doi: 10.1007/s13346-018-0557-x

Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

Abstract: Polyelectrolyte nanoparticle constructs (NPs) comprising salmon calcitonin (sCT), chitosan (CS), and hyaluronic acid (HA) were previously established as having anti-inflammatory potential when injected via the intra-articular (i.a.) route to a mouse model. We attempted to translate the formulation to a large animal model, the lipopolysaccharide (LPS)-stimulated equine model of joint inflammation. The aim was to manufacture under aseptic conditions to produce sterile pyrogen-free NPs, to confirm physicochemical characteristics, and to test toxicity and efficacy in a pilot study. NP dispersions were successfully formulated using pharmaceutical-grade source materials and were aseptically manufactured under GMP-simulated conditions in a grade A modular aseptic processing workstation. The NP formulation had no detectable pathogen or endotoxin contamination. NPs were then tested versus a lactated Ringer's solution control following single i.a. injections to the radiocarpal joints of two groups of four horses pre-treated with LPS, followed by arthrocentesis at set intervals over 1 week. There was no evidence of treatment-related toxicity over the period. While there were no differences between clinical read-outs of the NP and the control, two synovial fluid-derived biomarkers associated with cartilage turnover revealed a beneficial effect of NPs. In conclusion, NPs comprising well-known materials were manufactured for an equine i.a.-injectable pilot study and yielded no NP-attributable toxicity. Evidence of NP-associated benefit at the level of secondary endpoints was detected as a result of decreases in synovial fluid inflammatory biomarkers.
Get Full Text
Publication Date: 2018-06-28 PubMed ID: 29947020DOI: 10.1007/s13346-018-0557-xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research explores the development and testing of an anti-inflammatory nanocomplex made up of salmon calcitonin, chitosan, and hyaluronic acid. This was administered through intra-articular injections on an equine model inflamed by lipopolysaccharide. It was found to be non-toxic and potentially beneficial for reducing inflammation.

Research Goals and Methods

  • The primary aim of this research was to translate a previously successful anti-inflammatory nanocomplex, containing salmon calcitonin (sCT), chitosan (CS), and hyaluronic acid (HA), from a mouse model to a large animal model – specifically the lipopolysaccharide (LPS)-stimulated equine model of joint inflammation.
  • An additional goal was to produce these nanoparticle constructs (NPs) under sterile, aseptic conditions to ensure they were free of pathogens and endotoxins. The verification of their physiochemical characteristics was also essential.
  • The final part of their methodology was to test the toxicity and efficacy of these newly created NPs through a pilot study in horses.

Results and Findings

  • The researchers successfully formulated a sterile, aseptic nanocomplex using pharmaceutical-grade materials. This process occurred under Good Manufacturing Practices (GMP) conditions demonstrating its scalability and reproducibility.
  • Once administered via an intra-articular (i.a.) injection to the inflamed joints of the horses, there were no observable signs of toxicity from the nanocomplex over the study period.
  • Physically, clinical observations revealed no difference between horses treated with the NP and those treated with a control solution. However, when examining specific biomarkers associated with cartilage turnover in the synovial fluid, there was a noticeable benefit in the NP-treated animals.
  • This subtle, yet valuable, difference implied that the NP formulation had a positive effect on reducing inflammation at a cellular level. Even though this didn’t translate to apparent physical changes in this initial pilot study, it holds promise for further, in-depth investigations.

Conclusions and Further Implications

  • The researchers conclusively manufactured a nanocomplex for an equine intra-articular injection that showed no attributable toxicity. Beyond that, they found evidence of beneficial effects on secondary endpoints, chiefly decreased inflammatory biomarkers in synovial fluid.
  • This preliminary study forms a solid base for potential, more detailed research into the applications and effectiveness of this nanocomplex in treating joint inflammation in larger animal models or potentially in clinical settings.

Cite This Article

APA
Sladek S, Kearney C, Crean D, Brama PAJ, Tajber L, Fawcett K, Labberte MC, Leggett B, Brayden DJ. (2018). Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. Drug Deliv Transl Res, 8(5), 1421-1435. https://doi.org/10.1007/s13346-018-0557-x

Publication

Drug delivery and translational research
ISSN: 2190-3948
NlmUniqueID: 101540061
Country: United States
Language: English
Volume: 8
Issue: 5
Pages: 1421-1435

Researcher Affiliations

Sladek, Svenja
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Kearney, Clodagh
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Crean, Daniel
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Brama, Pieter A J
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Tajber, Lidia
  • School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Fawcett, Karolina
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Labberte, Margot C
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Leggett, Bernadette
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Brayden, David J
  • UCD School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland. david.brayden@ucd.ie.
  • UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. david.brayden@ucd.ie.
  • Veterinary Science Centre, University College Dublin, Dublin 4, Ireland. david.brayden@ucd.ie.

MeSH Terms

  • Animals
  • Arthrocentesis
  • Biomarkers / metabolism
  • Calcitonin / administration & dosage
  • Calcitonin / pharmacology
  • Chitosan / administration & dosage
  • Chitosan / pharmacology
  • Disease Models, Animal
  • Drug Carriers / chemistry
  • Horses
  • Hyaluronic Acid / administration & dosage
  • Hyaluronic Acid / pharmacology
  • Injections, Intra-Articular
  • Lipopolysaccharides / adverse effects
  • Nanoconjugates / chemistry
  • Nanoconjugates / toxicity
  • Pilot Projects
  • Synovial Fluid / metabolism
  • Synovitis / chemically induced
  • Synovitis / drug therapy
  • Synovitis / metabolism

Grant Funding

  • 13/RC/2073 / Science Foundation Ireland
  • 12/RC/2275 / Science Foundation Ireland
  • ISSF Clinical Primer Scheme / Wellcome Trust

References

This article includes 57 references
  1. J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):285-93
    pubmed: 16172519
  2. Equine Vet J. 2010 Jul;42(5):412-9
    pubmed: 20636777
  3. Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
    pubmed: 27137110
  4. Bioconjug Chem. 2016 Apr 20;27(4):855-62
    pubmed: 26734836
  5. J Control Release. 2018 Jan 10;269:189-213
    pubmed: 29146243
  6. Arthritis Rheum. 2009 Feb;60(2):513-23
    pubmed: 19180509
  7. Osteoarthritis Cartilage. 2015 Apr;23(4):532-43
    pubmed: 25582279
  8. Int J Pharm. 2015 Apr 30;484(1-2):8-15
    pubmed: 25701632
  9. Bone Joint Res. 2012 Nov 01;1(11):297-309
    pubmed: 23610661
  10. Langmuir. 2010 Jun 1;26(11):8829-35
    pubmed: 20155986
  11. Int J Pharm. 2012 Oct 15;436(1-2):75-87
    pubmed: 22814226
  12. J Control Release. 2013 Apr 28;167(2):120-9
    pubmed: 23391443
  13. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
    pubmed: 24462672
  14. Vet J. 2011 Oct;190(1):15-21
    pubmed: 20947396
  15. Osteoarthritis Cartilage. 2006 Aug;14(8):759-68
    pubmed: 16549372
  16. Adv Drug Deliv Rev. 2006 May 20;58(2):226-42
    pubmed: 16574267
  17. Expert Opin Drug Saf. 2017 Aug;16(8):897-902
    pubmed: 28627937
  18. Osteoarthritis Cartilage. 2016 Dec;24(12):2022-2041
    pubmed: 27492466
  19. Pharm Res. 2002 Feb;19(2):132-9
    pubmed: 11883639
  20. J Control Release. 2015 Sep 28;214:103-11
    pubmed: 26216396
  21. Pharm Res. 2002 Apr;19(4):403-10
    pubmed: 12033371
  22. Cochrane Database Syst Rev. 2015 Oct 22;(10):CD005328
    pubmed: 26490760
  23. J Musculoskelet Neuronal Interact. 2015 Jun;15(2):186-9
    pubmed: 26032211
  24. Nat Rev Drug Discov. 2005 Apr;4(4):331-44
    pubmed: 15803196
  25. Arthritis Res Ther. 2009;11(2):R35
    pubmed: 19272138
  26. Osteoporos Int. 2012 Jan;23(1):17-38
    pubmed: 21660557
  27. Mol Pharm. 2011 Oct 3;8(5):1887-98
    pubmed: 21882837
  28. J Bone Joint Surg Am. 2015 Dec 16;97(24):2047-60
    pubmed: 26677239
  29. Curr Opin Rheumatol. 2018 Jan;30(1):101-107
    pubmed: 28957964
  30. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S1-2
    pubmed: 26806186
  31. Expert Opin Drug Deliv. 2014 Feb;11(2):269-82
    pubmed: 24308404
  32. Nanomedicine. 2014 Oct;10(7):1391-9
    pubmed: 24709329
  33. Rheumatol Int. 2013 Feb;33(2):423-7
    pubmed: 22453526
  34. Ann Rheum Dis. 2013 Nov;72(11):1756-63
    pubmed: 23897772
  35. Int J Pharm. 2014 Dec 30;477(1-2):102-12
    pubmed: 25447822
  36. Acta Vet Scand. 1981;22(1):23-31
    pubmed: 7258028
  37. J Pharm Sci. 2008 Jun;97(6):2041-4
    pubmed: 17847072
  38. Nanomedicine (Lond). 2010 Jun;5(4):555-62
    pubmed: 20528451
  39. Osteoporos Int. 2008 Apr;19(4):479-91
    pubmed: 18071651
  40. Colloids Surf B Biointerfaces. 2017 Jun 1;154:33-39
    pubmed: 28288340
  41. Nat Rev Rheumatol. 2014 Jan;10(1):11-22
    pubmed: 24189839
  42. Expert Opin Drug Deliv. 2009 Jan;6(1):17-26
    pubmed: 19236205
  43. Arthritis Rheum. 1985 Apr;28(4):441-9
    pubmed: 3885961
  44. J Nanobiotechnology. 2012 Aug 31;10:38
    pubmed: 22937885
  45. Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):196-222
    pubmed: 26964477
  46. J Control Release. 1999 May 1;59(1):55-62
    pubmed: 10210722
  47. Innate Immun. 2014 Apr;20(3):327-36
    pubmed: 23884096
  48. J Nanomed Nanotechnol. 2011 Oct 25;2011(Suppl 5):001
    pubmed: 25035814
  49. Equine Vet J. 2009 Sep;41(7):693-9
    pubmed: 19927589
  50. Ann Rheum Dis. 2005 Aug;64(8):1132-6
    pubmed: 15695536
  51. Nat Mater. 2008 Mar;7(3):248-54
    pubmed: 18246072
  52. Int J Nanomedicine. 2013;8:3843-53
    pubmed: 24124369
  53. Osteoarthritis Cartilage. 2017 Oct;25(10):1577-1587
    pubmed: 28705606
  54. Osteoarthritis Cartilage. 2016 Sep;24(9):1509-17
    pubmed: 27143362
  55. AAPS J. 2012 Jun;14(2):282-95
    pubmed: 22407288
  56. Int J Pharm. 2002 Feb 21;233(1-2):239-52
    pubmed: 11897428
  57. Osteoarthritis Cartilage. 2012 Dec;20(12):1583-90
    pubmed: 22917743

Citations

This article has been cited 10 times.
  1. Duggan MJS, Kearney C, Baltrimaite M, Labberté MC, Gibney R, Brama PAJ. Refinement of the Lipopolysaccharide-Induced Synovitis Model in Equine Middle Carpal Joints. Animals (Basel) 2025 Aug 22;15(17).
    doi: 10.3390/ani15172474pubmed: 40941269google scholar: lookup
  2. Terlinden A, Jacquet S, Manivong S, Cullier A, Cassé F, Legendre F, Garcia AA, Roullin G, Moldovan F, Sirois P, Banquy X, Galéra P, Audigié F, Demoor M, Bertoni L. Double-blinded, randomized tolerance study of a biologically enhanced Nanogel with endothelin-1 and bradykinin receptor antagonist peptides via intra-articular injection for osteoarthritis treatment in horses. BMC Vet Res 2024 Dec 4;20(1):547.
    doi: 10.1186/s12917-024-04352-wpubmed: 39633332google scholar: lookup
  3. Liao HJ, Chen HT, Chang CH. Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis. Cartilage 2024 Sep 18;:19476035241276406.
    doi: 10.1177/19476035241276406pubmed: 39291443google scholar: lookup
  4. Goswami A, Ruhina Rahman SN, Ponneganti S, Gangipangi V, Vavialala H, Radhakrishnanand P, Selvaraju S, Mutheneni SR, Bharti S, Shunmugaperumal T. Intratympanic injections of emulsion-like dispersions to augment cinnarizine amount in a healthy rabbit inner ear model. Nanomedicine (Lond) 2024;19(21-22):1717-1741.
    doi: 10.1080/17435889.2024.2373042pubmed: 39041668google scholar: lookup
  5. Kearney CM, Korthagen NM, Plomp SGM, Labberté MC, de Grauw JC, van Weeren PR, Brama PAJ. A Translational Model for Repeated Episodes of Joint Inflammation: Welfare, Clinical and Synovial Fluid Biomarker Assessment. Animals (Basel) 2023 Oct 12;13(20).
    doi: 10.3390/ani13203190pubmed: 37893914google scholar: lookup
  6. Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labberté MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation. Front Vet Sci 2022;9:907616.
    doi: 10.3389/fvets.2022.907616pubmed: 35812845google scholar: lookup
  7. Huang H, Lou Z, Zheng S, Wu J, Yao Q, Chen R, Kou L, Chen D. Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage. Drug Deliv 2022 Dec;29(1):767-791.
    doi: 10.1080/10717544.2022.2048130pubmed: 35261301google scholar: lookup
  8. Kruel AVS, Ribeiro LL, Gusmão PD, Huber SC, Lana JFSD. Orthobiologics in the treatment of hip disorders. World J Stem Cells 2021 Apr 26;13(4):304-316.
    doi: 10.4252/wjsc.v13.i4.304pubmed: 33959220google scholar: lookup
  9. Bittar IP, Neves CA, Araújo CT, Oliveira YVR, Silva SL, Borges NC, Franco LG. Dose-Finding in the Development of an LPS-Induced Model of Synovitis in Sheep. Comp Med 2021 Apr 1;71(2):141-147.
    doi: 10.30802/AALAS-CM-20-000032pubmed: 33568256google scholar: lookup
  10. Sladek S, McCartney F, Eskander M, Dunne DJ, Santos-Martinez MJ, Benetti F, Tajber L, Brayden DJ. An Enteric-Coated Polyelectrolyte Nanocomplex Delivers Insulin in Rat Intestinal Instillations when Combined with a Permeation Enhancer. Pharmaceutics 2020 Mar 12;12(3).
    doi: 10.3390/pharmaceutics12030259pubmed: 32178442google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.